{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigydb2hs73gwaegyycrcymccwkbsfyd7muo66jkxyn6a5b7qwjsxe",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3modqcw2mweb2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigeqcjbx5xi7v3b4vcdpmlogwdbkjwot7oyb2g2rlz42tuymljsee"
    },
    "mimeType": "image/jpeg",
    "size": 59546
  },
  "path": "/2026/06/15/medicare-weight-loss-drugs-glp1-bridge-program-may-be-hard-to-end/?utm_campaign=rss",
  "publishedAt": "2026-06-15T15:25:14.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Health",
    "Pharma",
    "Politics",
    "chronic diseases",
    "drug pricing",
    "HHS",
    "Medicare",
    "Obesity",
    "politics",
    "STAT+",
    "weight loss"
  ],
  "textContent": "After July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.",
  "title": "STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end",
  "updatedAt": "2026-06-15T15:25:20.000Z"
}